1. Intravenous fosfomycin—back to the future
Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature 
B. Grabein, W. Graninger, J. Rodríguez Baño, A. Dinh, D.B. Liesenfeld 
Clinical Microbiology and Infection 
Volume 23, Issue 6, Pages (June 2017)
DOI: /j.cmi
Copyright © 2016 The Authors Terms and Conditions

2. Fig. 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart describing the search strategy.
Clinical Microbiology and Infection  , DOI: ( /j.cmi )
Copyright © 2016 The Authors Terms and Conditions

3. Fig. 2
Descriptive summary of the studies reviewed here. (a) Numbers of patients treated with intravenous fosfomycin by treatment indication as per MedDRA version BJI, bone and joint infections; UTI, urinary tract infections; CNS, central nervous system infections; SSTI, skin and soft-tissue infections. (b) Absolute numbers of microbiological isolates reported by pathogen.
Clinical Microbiology and Infection  , DOI: ( /j.cmi )
Copyright © 2016 The Authors Terms and Conditions

4. Fig. 3
Clinical efficacy in patients who were treated with intravenous fosfomycin compared with other antibiotic agents. Odds ratios (ORs) > 1 indicate increased clinical efficacy with fosfomycin. Diamonds indicate pooled ORs (± 95% CI).
Clinical Microbiology and Infection  , DOI: ( /j.cmi )
Copyright © 2016 The Authors Terms and Conditions